At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 3, 2026 at 16:05 ET
Tarsus reported Q3 2026 XDEMVY net product sales of $194.6M, up ~64% YoY and above the $190.8M consensus. However, the GAAP net loss widened to $668.3M ($14.40 per share) vs the $-1.77 consensus estimate, driven by $632.2M in acquired IPR&D expenses from the iRenix and Alkeus acquisitions. The underlying commercial momentum is strong, but the large one-time charges make headline earnings uninformative.
- XDEMVY net product sales $194.6M in Q3 2026, up ~64% YoY from $118.7M
- Revenue of $194.6M beat consensus of $190.8M
- GAAP net loss per share $(14.40) vs consensus $(1.77), driven by $632.2M in acquired IPR&D expenses
- Gross margin remained consistent at ~93%
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access